Thera-SAbDab

TAMTUVETMAB

>   Structural Summary
TherapeuticTamtuvetmab
TargetCD52
Heavy ChainEVKLLESGGGLVQPGGSMRLSCAGSGFTFTDFYMNWIRQPAGKAPEWLGFIRDKAKGYTTEYNPSVKGRFTISRDNTQNMLYLQMNTLRAEDTATYYCAREGHTAAPFDYWGQGTLVTVSS
Light ChainDIKMTQSPSFLSASVGDRVTLNCKASQNIDKYLNWYQQKLGESPKLLIYNTNNLQTGIPSRFSGSGSGTDFTLTISSLQPEDVATYFCLQHISRPRTFGGGTHLTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv Structure1bfo [Fvs: BA, DC, FE, HG]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Tamtuvetmab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 96.93%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 52B 52C 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 101 102 103 104 105 106 107 108 109 110 111 112 113
tamtuvetmab E V K L L E S G G G L V Q P G G S M R L S C A G S G F T F T D F Y M N W I R Q P A G K A P E W L G F I R D K A K G Y T T E Y N P S V K G R F T I S R D N T Q N M L Y L Q M N T L R A E D T A T Y Y C A R E G H T A A P F D Y W G Q G T L V T V S S
1bfo E V K L L E S G G G L V Q P G G S M R L S C A G S G F T F T D F Y M N W I R Q P A G K A P E W L G F I R D K A K G Y T T E Y N P S V K G R F T I S R D N T Q N M L Y L Q M N T L R A E D T A T Y Y C A R E G H T A A P F D Y W G Q G V M V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
tamtuvetmab D I K M T Q S P S F L S A S V G D R V T L N C K A S Q N I D K Y L N W Y Q Q K L G E S P K L L I Y N T N N L Q T G I P S R F S G S G S G T D F T L T I S S L Q P E D V A T Y F C L Q H I S R P R T F G G G T H L T V L
1bfo D I K M T Q S P S F L S A S V G D R V T L N C K A S Q N I D K Y L N W Y Q Q K L G E S P K L L I Y N T N N L Q T G I P S R F S G S G S G T D F T L T I S S L Q P E D V A T Y F C L Q H I S R P R T F G T G T K L E L K
>   Metadata
FormatCanine Whole mAb
IsotypeG2
Highest Clinical Trial (June '19)Unknown
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedAratana Pharmaceuticals
Conditions Approvedna
Conditions ActiveCanine T-cell lymphoma
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]